The Venous Thromboembolism drugs in development market research report provides comprehensive information on the therapeutics under development for Venous Thromboembolism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Venous Thromboembolism. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Venous Thromboembolism and features dormant and discontinued products.

GlobalData tracks 33 drugs in development for Venous Thromboembolism by 30 companies/universities/institutes. The top development phase for Venous Thromboembolism is phase i with 13 drugs in that stage. The Venous Thromboembolism pipeline has 33 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Venous Thromboembolism pipeline products market are: Jiangsu Hengrui Medicine, Translational Sciences and Acticor Biotech.

The key targets in the Venous Thromboembolism pipeline products market include Coagulation Factor X (Stuart Prower Factor or Stuart Factor or F10 or EC, Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC, and Plasminogen (Plasmin or PLG or EC

The key mechanisms of action in the Venous Thromboembolism pipeline product include Coagulation Factor X (Stuart Prower Factor or Stuart Factor or F10 or EC Inhibitor with seven drugs in Filing rejected/Withdrawn. The Venous Thromboembolism pipeline products include ten routes of administration with the top ROA being Oral and six key molecule types in the Venous Thromboembolism pipeline products market including Small Molecule, and Monoclonal Antibody.

Venous Thromboembolism overview

Venous thromboembolism (VTE) is a condition that occurs when a blood clot forms in a vein and blocks the blood flow. VTE can affect the deep veins of the legs or arms (deep vein thrombosis, or DVT) or the lungs (pulmonary embolism, or PE). VTE can cause serious complications such as tissue damage, organ failure, or death. VTE can be provoked by factors such as surgery, injury, infection, inflammation, or immobility. VTE can be prevented by using anticoagulant medications, compression stockings, or mechanical devices. VTE can be diagnosed by using tests such as ultrasound, computed tomography (CT) scan, or ventilation-perfusion (VQ) scan. VTE can be treated by using anticoagulant medications, thrombolytic medications, or surgical procedures.

For a complete picture of Venous Thromboembolism’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.